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OBJECTIVES Supplemental myocardial hypertrophy induced by insulin-like growth factor (IGF)-1 may
prevent transition from hypertrophy to heart failure under chronic mechanical overload.
BACKGROUND Several studies have suggested that IGF-1 treatment may be beneficial in chronic heart
failure. In addition, recent studies indicated that the amount of a-myosin heavy chain
(MHC) plays a significant hemodynamic role in large animals including humans.
METHODS We treated Dahl salt-sensitive hypertensive rats on a long-term basis with IGF-1. The effects
were compared with those produced by treatment using a sub-antihypertensive dose of
temocapril, an angiotensin-converting enzyme (ACE) inhibitor. At 11 weeks, when these rats
displayed compensated left ventricular hypertrophy (LVH), they were randomized to three
groups: 1) IGF group (3 mg/kg/day); 2) temocapril group (1 mg/kg/day); and 3) vehicle
(control) group.
RESULTS After 15 weeks, the control rats showed left ventricular (LV) enlargement and severe LV
dysfunction and rapidly died of pulmonary congestion (mean survival time: 16.8 6 0.5
weeks). The survival time was significantly shortened (15.6 6 0.3 weeks) in the IGF-1 group
but significantly prolonged (19.5 6 0.6 weeks) in the temocapril group. The rats in the IGF-1
group showed accelerated LV dilation and dysfunction. Of the several parameters investi-
gated, it was found that the relative amounts of MHC isoforms differed among the three
groups. The a-MHC mRNA level was decreased by 52% (p , 0.01) in the IGF group, while
it increased by 58% (p , 0.01) in the temocapril group compared with the control group.
These changes were related to the progression of LV dysfunction.
CONCLUSIONS Supplemental myocardial hypertrophy with long-term IGF-1 treatment may not be beneficial
if concentric LVH already exists. Our data suggest that IGF-1 may not protect myocardial
performance when its hypertrophic effect aggravates the reduction of a-MHC. By contrast,
the ACE inhibitor may improve myocardial function and prognosis by preventing the
down-regulation of this isoform. (J Am Coll Cardiol 2000;36:635–42) © 2000 by the
American College of Cardiology
Myocardial hypertrophy is an adaptive response to various
mechanical and hormonal stimuli, but it also represents an
initial step in the pathogenesis of many cardiac diseases that
ultimately progress to ventricular failure. The mechanisms
by which this condition eventually progresses to heart failure
are not fully understood (1). Several drugs such as
angiotensin-converting enzyme (ACE) inhibitors (2), beta-
blockers (3), and endothelin receptor blockers (4) have been
clinically introduced to prevent the progression to heart
failure. All of these drugs act to suppress excessive neuro-
humoral stimuli. However, their effects are limited, and
mortality and morbidity in heart-failure patients still remain
unacceptably high.
Insulin-like growth factor (IGF)-1, a 70 amino-acid basic
peptide, is an essential growth factor for somatic-cell pro-
liferation and differentiation during development, mediat-
ing the biological effects of growth hormone (GH) (5,6).
The IGF-1 also acts in an autocrine or paracrine manner on
myocyte growth and hypertrophy. Several studies have
suggested that GH or IGF-1 treatment may be beneficial in
chronic heart failure, and they have offered the possibility
that insufficient myocardial hypertrophy might be the trig-
ger mechanism for the transition to heart failure. In exper-
imental studies, GH or IGF-1 administration has brought
about improved hemodynamic profiles in heart-failure ani-
mals due to myocardial infarction (7,8). In a study of GH
treatment in patients with dilated cardiomyopathy, Fazio et
al. (9) showed favorable effects on cardiac function and
exercise capacity that corresponded to an increase in the
IGF-1 levels. In contrast, recent prospective randomized
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trials have failed to demonstrate substantial benefits of GH
treatment (10). Therefore, it is currently controversial
whether or not GH or IGF-1 administration can offer
therapeutic benefits in treating heart failure, and it is also
unclear what forms of heart failure these drugs may opti-
mally benefit (11). Further, the mechanism by which GH or
IGF-1 acts in failing myocardial tissues remains poorly
understood.
To address such questions, we utilized salt-sensitive
hypertensive rats in which the process from mechanically
compensated left ventricular hypertrophy (LVH) to heart
failure can be clearly observed (12–14). We investigated the
cardiovascular effects of chronic IGF-1 administration on
the cardiac geometry and function as well as the prognosis in
these animals. In addition, by comparing these effects with
those of an ACE inhibitor, we found that the qualitative
modulation rather than the quantitative supply of contrac-
tile proteins may be crucial for myocardial performance and
animal prognosis in transition to heart failure.
MATERIALS AND METHODS
Experimental animals and general protocols. In all, 46
male inbred Dahl salt-sensitive (DS) rats were used for the
experiments. They were obtained from Eisai Co. (Tokyo,
Japan) and were fed an 8% NaCl (high-salt) diet after six
weeks of age (15,16). As described previously, these DS rats
develop systemic hypertension and show concentric LVH at
the age of 11 weeks. At the subsequent age of 16 to 18
weeks, the DS rats showed LV dilation and global hypoki-
nesis and died of massive pulmonary congestion within a
week (12).
The 11-week LVH-DS rats were randomized into three
groups: those treated with recombinant human IGF-1
(rhIGF-1; Fujisawa Co., Osaka, Japan) at a daily dose of
3 mg/kg body weight (IGF-1 group); those treated with
temocapril hydrochloride, an ACE inhibitor (Sankyo Co.,
Tokyo, Japan) (17), of 1 mg/kg body weight/day (temoca-
pril group); or those treated with vehicle alone (control
group). The IGF-1 was dissolved in normal saline and was
administrated via a subcutaneous-implanted osmotic mini-
pump (model 2ML4, Alzet, Newark, Delware). Temocapril
was dissolved in distilled water containing 1% NaHCO3
and orally administrated once a day. In the control group,
normal saline (with no IGF-1) was continuously infused in
the same manner as in the IGF-1 group. In a preliminary
study, the subcutaneous pump implantation did not affect
echocardiographic findings or survival.
In the first protocol (n 5 8 in the IGF-1 group, and n 5
10 in the temocapril and control groups) the animals were
monitored on a day-by-day basis to assess their survival. The
body weight (BW), tail-cuff systolic blood pressure (SBP),
and the in vivo echocardiographic assessment of LV dimen-
sions and contraction were performed biweekly (12). The
relative wall thickness (RWT), the LV fractional shortening
(FS), and the LV mass were estimated from the values of
LV end-diastolic diameter (EDD), end-systolic diameter
(ESD), and end-diastolic posterior wall thickness (PWT) as
described previously (18). In the second protocol (n 5 6 in
each group), at the age of 15 weeks (4 weeks after the
initiation of drug treatment), the rats were deeply anesthe-
tized with sodium pentobarbital. The LV was rapidly
excised, frozen in liquid nitrogen, and stored at 280°C until
use.
IGF-1 Radioimmunoassay. At 15 weeks, before sacrific-
ing the animals, blood samples were collected in a heparin-
ized syringe and centrifuged, and the plasma was obtained
and stored at 220°C before analysis. Serum rhIGF-1 levels
were measured by radioimmunoassay (RIA) as reported
previously (19). In brief, IGF-1 was separated from binding
proteins by acid/ethanol precipitation. Standard curves were
generated using rhIGF-1. The RIA used a rabbit anti-
human IGF-1 antibody, which does not cross-react with rat
IGF-1 at the dilutions used.
Collagen hydroxyproline assay. A part of the frozen LV
tissue was lyophilized to constant dry weight. Dry samples
were weighed and homogenized thoroughly in distilled
water. The homogenates were hydrolyzed in alkali and the
hydroxyproline concentration was determined using the
colorimetric method developed by Stegemann et al. (20).
Collagen concentration in the myocardium was calculated
by assuming that collagen weighs 7.46 times the measured
weight of hydroxyproline (21).
Northern blot analysis. Total RNA was isolated from the
LV tissue using the acid guanidinium thiocyanate-phenol-
chloroform method. Total RNA (20 mg) was subjected to
formaldehyde/agarose-gel electrophoresis and transferred to
nylon filters by overnight capillary blotting. The filters were
hybridized with the following 32P-labeled cDNA probes
listed below. The cDNA probes were radiolabeled with
[a-32P]dCTP (Amersham) using a random-priming
method. The blots were analyzed with a FUJIX bioimage
analyzer BAS 2000. Results were normalized with signals of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA.
The cDNA probes used in this study were the following:
1) atrial natriuretic peptide (ANP), a 362-bp fragment
isolated by reverse transcriptase–polymerase chain reaction
(RT-PCR) amplification with primers complementary to
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AT-II 5 angiotensin-II
DS 5 Dahl salt-sensitive
FS 5 fractional shortening
GAPDH 5 glyceraldehyde-3-phosphate dehydrogenase
GH 5 growth hormone
IGF 5 insulin-like growth factor
LVH 5 left ventricular hypertrophy
MHC 5 myosin heavy chain
RWT 5 relative wall thickness
SERCA 5 sarcoplasmic reticulum Ca21 ATPase
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the published sequence for rat mRNA (22); 2) myosin heavy
chain (MHC), a 524-bp fragment isolated by RT-PCR
amplification with primers complementary to the published
sequence for rat mRNA (23). Because this fragment was
98.5% identical, it crossed with both a- and b-MHC
isoforms (total MHC); 3) sarcoplasmic reticulum Ca21-
ATPase (SERCA) 2a, a 518-bp fragment isolated by
RT-PCR amplification of rabbit cardiac total RNA corre-
sponding to nucleotides 2617-3359 of the cDNA encoding
the rabbit cardiac/slow twitch skeletal muscle sarcoplasmic
reticulum Ca21-ATPase (24); 4) GAPDH, the human
cDNA purchased from the American Type Culture Collec-
tion. The PCR products were purified and subcloned into
pBluescript (Stratagene). The DNA sequences were con-
firmed by dideoxy-chain termination.
“Hot” RT-PCR analysis of MHC isoform mRNA. The
first-strand cDNA was synthesized with a cDNA synthesis
kit (Pharmacia). ‘Hot’ RT-PCR was performed as previ-
ously described by Petrou et al. (25). In brief, PCR
amplifications were achieved with the following oligonucle-
otides: forward primer, GAGGCGGTGCAGGAGTG-
TAG; and reverse primer, ACCTGGGACTCGGCAAT-
GTC, which were identical to sequences for both rat a- and
b-MHC isoforms (23). The PCR was performed in a 50-ml
reaction volume containing 200 mmol/liter dNTP, 40
mmol/liter of each specific primer, 10 mmol/liter of Tris-
HCl, 50 mmol/liter of KCl, 1.5 mmol/liter of MgCl2,
0.001% gelatin, 1.5 U of Taq polymerase (Takara, Japan),
and 1 mCi of 32P-dCTP (Amersham). The iso-RNAs were
distinguished by digestion of 10 ml of the PCR reaction
mixture with 10 U of Tru 9I (10 U/ml, Promega) in a
standard buffer at 65°C for 120 min. Fragments (a-MHC,
524 base pairs; b-MHC, 391 and 133 base pairs) were
separated on a 5% polyacrylamide gel and analyzed with the
bioimage analyzer. The ratio between the two complemen-
tary isoforms was determined.
Statistical analysis. The animal survivals were analyzed by
standard Kaplan-Meier analysis with the log-rank test. The
unpaired Student t-test was employed for other statistical
comparisons between two groups. Relationships between
two variables were tested by linear regression analysis. The
main effects of the drugs were tested using a two-factor
analysis of variance (ANOVA) for repeated measures, and
differences at specific time points between the groups were
assessed using one-factor ANOVA with post hoc compar-
isons by the Fisher protected least-significant-difference
test. In all tests, a p value ,0.05 was considered statistically
significant.
RESULTS
Survival rate. Figure 1 shows the survival curves of the
treated rats. All rats in the control group died of LV
dysfunction and pulmonary congestion between 14.5 and
18.5 weeks (mean 6 SEM; 16.8 6 0.5 weeks). The survival
rate at 17 weeks was 50.0% in the control group, 12.5% in
the IGF group, and 90.0% in the temocapril group. The
Kaplan-Meier survival analysis demonstrated a significant
shortening of survival in the IGF-1 group (15.6 6 0.3
weeks) compared with that in the control group (p 5
0.022). In contrast, the ACE inhibitor treatment produced
a substantial improvement in survival (19.5 6 0.6 weeks)
compared with that of the control group (p , 0.01). The
longest survival time in the temocapril group was 22.7
weeks. The difference in survival rate between the IGF-1
and temocapril groups was significant at p , 0.001.
We investigated several parameters to determine whether
significant differences could be found among the three
groups that might correlate with these differences in sur-
vival.
SBP and echocardiographic changes. There were no sig-
nificant differences in in vivo SBP among the three groups
(Table 1). Figure 2 demonstrates changes of EDD (A),
LV/BW (B), RWT (C), and LV FS (D) during the
four-week drug intervention. In the IGF-1 group, the EDD
and LV/BW were increased by 15% and 18%, respectively,
over the control group. In contrast, in the temocapril group,
these increases were significantly smaller than those in the
control group (by 18% and 14%, respectively). The RWT
decreased by 5% to 9% in all three groups during the
treatment course, but no significant difference was found. At
Figure 1. The effect of human recombinant IGF-1 and temocapril on
animal survival. Kaplan-Meier survival curves for the IGF-1-treated group
(n 5 8; open circles), the temocapril-treated group (n 5 10; filled circles),
and the control group (n 5 10; open inverted triangles). The IGF-1,
temocapril, or placebo was administrated from 11 weeks of age. *p , 0.01
or #p , 0.05 vs. control (log-rank test).
Table 1. Somatic and Cardiac Growth at 15 Weeks
Group IGF Temocapril Control
SBP (mm Hg) 255 6 5 246 6 5 248 6 4
BW (g) 351 6 11* 355 6 9* 319 6 10
TL (mm) 52.7 6 0.4 54.2 6 0.4*† 52.8 6 0.4
LV (g) 1.41 6 0.03* 1.14 6 0.03† 1.21 6 0.03
LV/BW (mg/g) 4.02 6 0.12 3.22 6 0.08*† 3.82 6 0.06
LV/TL (mg/mm) 26.7 6 0.6* 21.1 6 0.4*† 23.0 6 0.4
RV (g) 0.24 6 0.01* 0.21 6 0.01† 0.20 6 0.01
RV/BW (mg/g) 0.68 6 0.03 0.59 6 0.01† 0.63 6 0.01
RV/TL (mg/mm) 4.5 6 0.2* 3.8 6 0.1† 3.8 6 0.1
SBP 5 systolic blood pressure; BW 5 body weight; TL 5 tibial length; LV 5 left
ventricular weight; RV 5 right ventricular weight. Values are mean 6 SEM.
*p , 0.05 vs. control group. †p , 0.05 vs. IGF group.
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15 weeks, the LV FS in the IGF group (45 6 3%) was not
significantly different from that in the control group (49 6
2%), although it tended to decrease (p 5 0.08). The LV FS
in the temocapril group (59 6 1%) was significantly higher
(p , 0.05) than that in either the IGF or control group.
Thus, while the chronic administration of IGF-1 induced
supplemental LVH, it did not prevent progressive LV
dysfunction. In contrast, chronic treatment with ACE
inhibitor (at a dosage without hypotensive effect) prevented
the progressive LVH, which was associated with a preserved
LV contractile state.
Somatic and cardiac growth at 15 weeks. In the IGF-1
group, rats showed a significantly greater increase in body
weight than did those in the control group, even in the
second week of treatment (data not shown). At 15 weeks
(Table 1) the difference in BW reached 15% (p , 0.05).
Both the LV and right ventricular (RV) weights were
greater by 17% (p , 0.05) and 20% (p , 0.05), respectively.
The LV mass index normalized to the tibial length (LV/
TL) was also significantly greater (p , 0.01). In contrast, in
the temocapril group, while the BW at 15 weeks was 8%
greater (p , 0.01), the LV and RV weights did not increase
over those of the control group (p 5 0.08 and 0.48,
respectively). Consequently, the LV/TL was significantly
reduced by 8% (p , 0.05).
Serum IGF-1 levels. At 15 weeks, exogenous rhIGF-1
levels were measured by RIA. In the temocapril and control
groups, plasma rhIGF-1 was not detected. In the IGF-1
group, the level was 875 6 126 ng/ml (n 5 7).
The mRNA levels of ANP, SERCA2a, and MHC iso-
forms, and collagen content in LV. The LV tissue
mRNA levels of ANP are shown in Table 2. Although these
values tended to decrease in the IGF-1 and temocapril
groups, no significant changes were shown in ANP mRNA
expression during the treatment course. It was also evident
that the SERCA2a mRNA levels were not affected by
IGF-1 or ACE inhibitor treatments in this experimental
protocol (Table 2).
Figure 2. The effect of human recombinant IGF-1 and temocapril on echocardiographic data. The graphs show serial transthoracic echocardiographic
measurements, LV end-diastolic dimension (LV EDD) (A); estimated LV weight to body weight ratio (LV/BW) (B); relative wall thickness (RWT) (C);
and LV fractional shortening (FS) (D), for the IGF-1-treated group (n 5 8; open circles), the temocapril-treated group (n 5 10; filled circles), and the
control group (n 5 10; open inverted triangles). Values are expressed as mean 6 SEM. *p , 0.05.
Table 2. mRNA Levels and Collagen Content at 15 Weeks
Group IGF Temocapril Control
ANP mRNA (AU) 0.91 6 0.14 0.83 6 0.13 1.00 6 0.17
SERCA2a mRNA (AU) 0.98 6 0.27 1.10 6 0.20 1.00 6 0.17
Collagen content (mg/mg) 23.1 6 0.7 23.5 6 1.3 23.7 6 0.9
ANP 5 atrial natriuretic peptide; SERCA 5 sarcoplasmic reticulum Ca21-ATPase. AU indicates arbitrary units normalized to
GAPDH mRNA (the values of the control group were set at 1.0 and the remaining values were adjusted accordingly). Values
are mean 6 SEM.
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No significant differences were seen in the collagen
concentration in the LV myocardium, calculated from the
hydroxyproline content, among the three groups (Table 2).
Thus, chronic IGF-1 administration or ACE inhibitor
therapy of sub-antihypertensive dosage did not affect colla-
gen accumulation, at least during the observation period.
The total amount of MHC mRNA expression was
measured by Northern blot analysis (as the value normalized
to GAPDH mRNA expression), while the ratio of a to b
isoforms was determined by “Hot” RT-PCR analysis using
the same tissue samples (Fig. 3). The amount of a or b
isoform mRNA was calculated from these measures. No
significant differences existed in the total MHC mRNA
levels among the three groups (p 5 0.31), while the level in
the IGF-1 group tended to decrease and that in the
temocapril group tended to increase (Fig. 3A). In contrast,
the ratio of a- to b-MHC mRNA was decreased by 53% in
the IGF-1 group (0.23 6 0.02) and increased by 45% in the
temocapril group (0.71 6 0.04), when compared with this
ratio in the control group (0.49 6 0.09; p , 0.01 between
any two groups). By adapting the ratio values to the total
amount of MHC mRNA, we found that the a-MHC
mRNA level was decreased by 52% in the IGF-1 group
(p , 0.01 vs. both the control and temocapril groups), while
it increased by 58% in the temocapril group (p , 0.01 vs.
the control group) (Fig. 3B). Meanwhile, there were no
differences in the b-MHC mRNA levels among the three
groups (Fig. 3C). From these results, we plotted the
relationships between the a-MHC mRNA level and the
corresponding LV function (FS) for each animal. As shown
in Figure 4, there was a strong correlation (r 5 0.85, p ,
0.01) between these two measures.
DISCUSSION
In contrast to our initial hypothesis, the hypertensive rats
treated with hr IGF-1 demonstrated a poorer prognosis
than did untreated, control animals. Supplemental hyper-
trophy with IGF-1 thus merely accelerated LV dilation and
functional deterioration in the rat with LVH. Conversely,
chronic ACE inhibition with a sub-antihypertensive dose in
these hypertensive animals demonstrated a longer survival
that was associated with reduced LV mass and improved LV
function. Further investigation indicated that the MHC-
isoform transcript in the myocardium, rather than the total
myocardial mass, was a marker for distinguishing between
and characterizing these animal groups. Thus, our data are
consistent with the idea that the qualitative modulation of
contractile proteins should be crucial for myocardial perfor-
mance and animal prognosis, and the chronic IGF-1 treat-
ment may not be effective when it aggravates such modu-
lation of the contractile proteins.
The IGF-1 treatment in heart failure animals. In previ-
ous reports, it was confirmed that chronic IGF-1 or GH
administration in normal rats and mice caused substantial
myocardial hypertrophy, which was associated with aug-
mented myocardial contractility in vivo as well as in vitro
(7,26,27). In contrast, the effects of such treatments under
pathological conditions are controversial. Using the
myocardial-infarction rats with LV dysfunction, Duerr et al.
(7) reported that chronic IGF-1 treatment enhanced LVH
and improved function, which appeared to be due primarily
to the reduction in systemic vascular resistance. Cittadini et
al. (28) showed the suppression of early LV remodeling and
preservation of LV function after three weeks of treatment
Figure 3. Results of measurement of the MHC mRNA in the LV
myocardium of each group. The ratios of MHC isoform mRNA and total
MHC mRNA (A) were measured by “Hot” RT-PCR (D, upper panel)
and Northern blot analysis (D, lower panel), respectively. The amount of
a (B) or b (C) isoform mRNA was calculated from these measures. Values
are expressed as mean 6 SEM. *p , 0.05.
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with GH. In contrast, Shen et al. (11) demonstrated that a
four-week GH treatment did not affect LV performance or
systemic vascular dynamics in heart failure dogs under rapid
ventricular pacing. These inconsistent observations could be
due to differences in the pathogenesis of heart failure and
possible differences between IGF-1 and GH treatments
(27). However, it may be worth emphasizing that, essen-
tially, these animals were already decompensated with
decreased RWT ratios when the treatment with IGF-1 was
started. In contrast, in the present study, the administration
of IGF-1 was begun while the cardiac function was main-
tained and the LV showed a typical concentric pattern.
Thus, the present study examined for the first time whether
the chronic IGF-1 treatment could exert beneficial effects
on the primary prevention of heart failure in the setting of
existing LVH.
Possible contributions of endogenous IGF-1 to heart
failure. Acquired abnormalities of the GH/IGF-1 axis
have been described in severe heart failure, and it was
reported that deficient IGF-1 may predict altered body
composition, as well as cytokine and neurohumoral activa-
tions in human heart failure (29). These considerations
suggest that the efficacy of IGF-1 treatment might be
associated with existing decreases in plasma IGF-1. A
possible relationship between impaired IGF-1 utilization
and elevated plasma angiotensin-II (AT-II) levels was
reported in Sprague-Dawley rats (30). In addition, DS rats
with high-salt diet may be insulin-resistant, which may
cause reduced bioavailability of IGF-1 (31,32). Failure of
chronic IGF-1 treatment to prevent the transition to heart
failure in our model could be associated with these condi-
tions. However, the extraordinarily high concentration of
serum IGF-1 produced definitive somatic as well as cardiac
growth in our experimental setting. Our study especially
focused on the stage before heart failure. In addition, as
reported previously (30), the hypertensive DS rats showed
normal plasma AT-II (but see below regarding tissue
AT-II) and IGF-1 levels.
Effects of IGF-1 on LV myocardium in transition to
heart failure. With the same experimental protocol, we
previously reported the significant activation of the LV
tissue angiotensin-II system during the development of
compensatory hypertrophy, which was sustained even after
the transition to heart failure (manuscript under consider-
ation). Chronic ACE inhibition with temocapril signifi-
cantly suppressed LVH, resulting in the preservation of LV
performance and improvement of survival. In the present
study, we treated rats with temocapril in a dose that was
1/20th of the previous dose so as to make its anti-
hypertensive effects negligible. Even with this smaller
amount, ACE inhibition consistently showed an anti-
hypertrophic effect and an improvement in survival. Taken
together with the results from the IGF-1 group, we further
confirmed that the LV myocardial mass could not provide
information on the animal’s condition, at least not directly.
But why was the additional hypertrophy unable to reduce
the mechanical stress of the unit myocardium, thus resulting
in progression of LV dysfunction? One possibility could be
morphological changes of the ventricle. As shown in Figure
2C, the change of values of the relative wall thickness in the
IGF group was larger than that in the control or ACE
inhibitor group, although the levels were not statistically
significant. Combined with relative changes in EDD (Fig.
2A), the data indicate that IGF treatment increased LV
eccentricity. Thus, myofibrillar supply by IGF treatment
might accelerate eccentric ventricular growth and the ad-
verse process of remodeling in the hypertrophied myocar-
dium.
Another possibility is an alteration in the tissue compo-
nents or in the subcellular proteins that regulate the cell
contractions. Because massive fibrosis is common in hyper-
trophic hearts of patients with acromegaly (6), we quanti-
tatively assessed the hydroxyproline content in the LV
tissue. However, at least during the examination period, the
collagen content did not differ among the groups and it was
not associated with the LV function. Abnormalities of Ca21
handling have been reported as a candidate for producing
cardiac dysfunction (33). Tajima et al. (34) reported that
long-term GH therapy improved contractile reserve with an
increase of SERCA2a expression in rats with postinfarction
heart failure. However, we found that there was no change
of SERCA2a mRNA in our animals with IGF-1 or
temocapril. In addition, the ANP mRNA levels at 15 weeks
were equally elevated among the groups. Taken together, in
the present study, it appeared not likely that either the
extracellular matrix or the subcellular components such as
Ca21 handling proteins played critical roles. Further inves-
tigations are needed to establish the effects of chronic
IGF-1 therapy on these components by using animal
models in which their changes are clearly demonstrated.
The remaining possibility was the characteristic changes
of myofibrillar components. Along with the process of
Figure 4. Relationship between a-MHC mRNA level and LV function in
all groups. The linear regression analysis between a-MHC mRNA level
and LV fractional shortening (FS) shows a tight correlation (r 5 0.857,
p , 0.01). Open circles, filled circles, and open inverted triangles
indicate rats of the IGF, temocapril, and control groups, respectively.
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pressure-overload hypertrophy, our animals showed an in-
crease in b-MHC mRNA expression with a reciprocal
decrease in a-MHC mRNA, a well-established fetal-type
gene re-expression in the hypertrophic rodent heart. In
these rats, at the beginning of the pharmacological treat-
ments (at 11 weeks of age), the ratio of a- to total MHC
mRNA was 54.6% (n 5 5, unpublished data), which
decreased to 31.5% during the following four weeks (in the
control group). Interestingly, in contrast to the temocapril
group, the reduction of a-MHC was accelerated in the
IGF-1 group.
In addition, our regression analysis demonstrated an
intimate relationship between the levels of a-MHC mRNA
and the LV FS in all three animal groups. Because a-MHC
has triple the ATPase activity of b-MHC, the expression
ratio of these isoforms may be critical to maintain contrac-
tile velocity and diastolic relaxation with a heart rate over
300 beats/min such as in the rat heart (35,36). Of course, as
we have not determined the relation between the mRNA
abundance and the amount of MHC isoform protein, a
linear relationship may not necessarily imply a direct role of
the a-MHC mRNA on the contractile properties of the
diseased myocardium. Other unmeasured compositional
changes in the myocardium may contribute to the progres-
sion of LV dysfunction. However, the MHC isoform
finding at least supports our hypothesis that IGF-1 and
ACE inhibitors cause different characteristic changes in the
myofibrillar components, which in turn affects prognosis.
Studies of Donath et al. (37) do not agree with our
results. However, other reports have shown that IGF-1 or
GH caused down-regulation of myocardial a-MHC in vitro
and in vivo as in our case (25,38). Mayoux et al. (26)
reported that chronic GH hypersecretion in rats leads to a
decrease in the proportion of a-MHC both at the protein
and mRNA levels. Concomitantly, in their skinned fiber
study, increases in maximal active tension and stiffness were
observed in the GH rats, indicating an increase in the
number of active cross-bridges. Stro¨mer et al. (27) demon-
strated an enhancement of contractility that was associated
with an impairment of relaxation by chronic IGF-1 or GH
treatment in normal rats. They also suggested that these
changes were most likely caused by an alteration at the level
of the myofilament because of insignificant changes in the
corresponding Ca21 transients. Thus, our hypothesis re-
garding the IGF-1-mediated changes in the properties of
the contractile component appears to be consistent with
their observations. Indeed, at 13 weeks, our IGF-1-treated
rats showed a tendency toward enhancement of systolic
performance by in vivo echocardiography (FS: 58.5 6 1.4%
in the IGF group vs. 52.5 6 2.7% in the control group; p 5
0.152). At 15 weeks, however, rats in the IGF-1 group
showed a marked progression of LV dysfunction. These
results suggest that IGF-1 may produce a better contractile
performance as a net result in the normal myocardium, but
this beneficial effect may be limited in the diseased myocar-
dium, which is already deficient in several functional advan-
tages such as a-MHC abundance.
Effects of IGF-1 versus ACE inhibitor on MHC com-
position. In rodents, the MHC composition of the ven-
tricular myocardium was reported to be .80% a-isoform.
Numerous stimuli such as thyroid hormone, exercise, aging,
and pressure overload have been shown to change the MHC
composition (39). Our rat model showed a 68% reduction of
a-MHC mRNA abundance during the transition to heart
failure (from 11 to 17 weeks). Therefore, a modification of
a-MHC expression might be critical in LV function and
prognosis in our animals. In contrast, in humans, because it
had been reported that the normal heart is largely devoid of
a-MHC (40,41), the isoform shift in developing heart
failure was once thought to be irrelevant. However, recently,
using the RT-PCR method, Nakao et al. (42) reported that
a-MHC mRNA constituted a significant part of the total
MHC gene expression in the normal human LV (a/total
MHC mRNA: 33 6 19%), which substantially decreased in
end-stage failing human LV (2.2 6 3.5%). Lowes et al. (43)
also observed the similar change of a-MHC mRNA ex-
pression in human hearts in disease. Other investigators
concluded that the reduction of a-MHC mRNA expression
corresponded to decreased myosin or myofibrillar ATPase
activity in the failing human heart (44,45) and was associ-
ated with the systolic dysfunction. Therefore, a modification
of a-MHC expression might be critical not only in small
animals but also in larger animals, including humans.
The beneficial effects of ACE inhibitors on failing myo-
cardium are repeatedly documented in both experimental
and clinical settings (3,46). Our present study supports the
idea that an increase in a-MHC gene expression should be
one of the major mechanisms for the beneficial effect of
ACE inhibitors. In contrast, our study suggests that clinical
application of IGF-1 or GH should be undertaken cau-
tiously in terms of such alterations of the contractile
elements. Further and long-term studies in other animal
models and in humans are needed to determine critical
effects of this MHC shift in its relation to ventricular
relaxation, force-frequency responses, and energy utiliza-
tion.
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